MME and myocardial infarction: Here, it is important to mention that the administration of an angiotensin receptor–neprilysin inhibitor (ARNI), such as sacubitril/valsartan, is recommended in patients at risk of adverse cardiac remodelling and HF post-MI [26], and in cases of already established HF with reduced ejection fraction as a result of MI [27].